Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jenny C. Chang"'
Autor:
Sibylle Loibl, Chiun-Sheng Huang, Max S. Mano, Eleftherios P. Mamounas, Charles E. Geyer, Michael Untch, Jean-Christophe Thery, Ingo Schwaner, Steven Limentani, Niklas Loman, Kristina Lübbe, Jenny C. Chang, Thomas Hatschek, David Tesarowski, Chunyan Song, Sanne Lysbet de Haas, Thomas Boulet, Chiara Lambertini, Norman Wolmark
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-6 (2022)
Abstract Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated
Externí odkaz:
https://doaj.org/article/c268c669d03547e1b3867ec85f83f413
Autor:
Andrew W. Chung, Anthony J. Kozielski, Wei Qian, Jianying Zhou, Ann C. Anselme, Alfred A. Chan, Ping-Ying Pan, Delphine J. Lee, Jenny C. Chang
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract Triple-negative breast cancer (TNBC) patients with mesenchymal stem-like (MSL) subtype have responded poorly to chemotherapy whereas patients with basal-like 1 (BL1) subtype achieved the best clinical response. In order to gain insight into
Externí odkaz:
https://doaj.org/article/f35ee9f823934baea9f5adb11e89df96
Autor:
Andrew W, Chung, Anthony J, Kozielski, Wei, Qian, Jianying, Zhou, Ann C, Anselme, Alfred A, Chan, Ping-Ying, Pan, Delphine J, Lee, Jenny C, Chang
Publikováno v:
NPJ breast cancer. 8(1)
Triple-negative breast cancer (TNBC) patients with mesenchymal stem-like (MSL) subtype have responded poorly to chemotherapy whereas patients with basal-like 1 (BL1) subtype achieved the best clinical response. In order to gain insight into pathways